Headache News and Research

Latest Headache News and Research

MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults

Allergan, and MAP Pharmaceuticals, today announced a collaboration within the United States for LEVADEX, a self-administered, orally inhaled therapy that has completed Phase III clinical development for the treatment of acute migraine in adults.

31 Jan 2011

Loyola inaugurates clinic exclusively to treat children with headaches

Fortunately, in most cases the causes of childhood headaches are usually no cause for alarm, Schnitzler said. Children can get headaches from stress, anxiety, inadequate sleep, vision problems, caffeine or food sensitivities. To help pinpoint the cause, Loyola has opened a clinic that's exclusively devoted to treating children with headaches.

31 Jan 2011

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.

29 Jan 2011

FDA approves GRALISE Tablets for treatment of PHN

Depomed, Inc. today announced that US FDA has approved GRALISE (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia, which is pain following healing of the rash associated with shingles.

29 Jan 2011

Composer Fr-d-ric Chopin probably had temporal lobe epilepsy

The composer Fr-d-ric Chopin, who regularly hallucinated, probably had temporal lobe epilepsy throughout his short life, reveals research published online in Medical Humanities. Hallucinations typically feature in seizure disorders, they say.

25 Jan 2011

PediatRx announces first-ever revenues and successful launch of GRANISOL

PediatRx Inc.is pleased to provide an update on activities for the fiscal third quarter. Among its achievements, the hospital specialty pharmaceutical company reported its first-ever revenues and successfully launched GRANISOL™, the company's first commercial entry.

24 Jan 2011

CT scans can help physicians to diagnose abdominal pain, reduce health care costs

The use of CT scanning to evaluate abdominal pain in emergency departments can help physicians arrive at a diagnosis quickly and decisively. A study conducted at Massachusetts General Hospital and appearing in the February issue of the American Journal of Roentgenology also finds that information provided by CT scans changed treatment plans for almost half the patients studied and significantly reduced probable hospital admissions.

24 Jan 2011

Preliminary top-line results from levomilnacipran Phase III study for MDD

Forest Laboratories, and Pierre Fabre Medicament today announced preliminary top-line results from a Phase III study of levomilnacipran for the treatment of major depressive disorder.

20 Jan 2011

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Vertex Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for telaprevir and granted the company's request for six-month Priority Review. Telaprevir is Vertex's lead medicine in development for people with genotype 1 chronic hepatitis C.

20 Jan 2011

Chelsea reports top-line data from Phase III NORTHERA extension study in NOH

Chelsea Therapeutics International, Ltd. reported new 12-month data from Study 303, a safety extension study from its Phase III NORTHERA™ (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Preliminary, top-line results demonstrate Northera provides clinically meaningful and durable symptomatic improvements in patients with NOH throughout a one-year observation period.

20 Jan 2011

Brains of migraine sufferers show higher proportion of lesions of brain microvessels

Recent work, in particular the CAMERA study, has used MRI to study the brains of migraine sufferers and has shown that a higher proportion of these patients exhibit lesions of the brain microvessels than the rest of the population.

20 Jan 2011

Cadence launches OFIRMEV pain medication in the U.S.

Cadence Pharmaceuticals, Inc. today announced the launch of OFIRMEV™ (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States. The U.S. Food and Drug Administration (FDA) approved OFIRMEV in November 2010 for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.

18 Jan 2011

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Eli Lilly Canada is pleased to announce the Health Canada approval of BYETTATM for the treatment of adults with type 2 diabetes.

18 Jan 2011

Ruptured brain aneurysm treated through the nose

During breakfast one Sunday, Alfreda Cordero was struck suddenly and violently by the worst headache she had ever experienced. A day later, she would make medical history as the first person to have a ruptured brain aneurysm treated through the nose.

14 Jan 2011

American Heart Association proposes new metrics to monitor quality of stroke care

The American Heart Association/American Stroke Association has proposed metrics that healthcare professionals can use to monitor the diagnosis and treatment of patients at stroke centers to help improve the quality of care stroke patients receive.

14 Jan 2011

Adjunctive lacosamide reduces seizures and improves responder rates

Comprehensive analyses of pooled data from three randomized, double-blind, placebo-controlled Phase II/III trials showing the efficacy and tolerability of Vimpat® (lacosamide) C-V for patients with partial-onset seizures, regardless of the type of concomitant AED used, have been published in the drug evaluation journal, CNS Drugs.

13 Jan 2011

NSAIDs raise risk of heart disease: Study

A new study published online in the British Medical Journal explores the relative safety of non-steroidal anti-inflammatory medications (NSAIDs), commonly used to treat joint and muscle aches and pain and concludes that NSAIDs significantly increase the risk of cardiovascular events in patients who take them regularly.

12 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro in Germany and the UK

Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA).

11 Jan 2011

Less than 7% of U.S. seniors get shingles vaccination

Although a vaccine to prevent shingles has been available since 2006, less than 7 percent of U.S. seniors — the demographic most frequently affected by the disease — chose to receive the vaccination as of 2008, finds a new study from the Centers for Disease Control and Prevention (CDC).

11 Jan 2011